Autologous Cultured Chondrocytes

Summary

Autologous Cultured Chondrocytes (CHEMBL5315092) is an approved unknown; indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315092
Name	Autologous Cultured Chondrocytes
Type	Unknown
Max phase	4

Also known as: Autologous cultured chondrocytes, Carticel, Maci, AUTOLOGOUS CULTURED CHONDROCYTES

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03588975	PHASE3	RECRUITING	A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).